

Is biopsy the next step?

Find out with Prostate Health Index from ARUP Laboratories.

Prostate Health Index (PHI) is a safe, less-invasive step in the process of diagnosing prostate cancer. It's a simple, FDA-approved blood test that uses an algorithm to assess total PSA, free PSA, and p2PSA.

Using PHI as part of a multivariable diagnostic process can significantly reduce the number of unnecessary biopsies.

Be confident in your diagnostic decisions about prostate cancer.

Prostate Health Index (PHI)

	PROSTATE HEALTH INDEX (3000134)	4KSCORE (2014059)
Ordering recommendation	<ul style="list-style-type: none">Individuals aged 50 or olderTotal PSA between 4 and 10 ng/mLDRE not suspicious for cancer (specimens for testing should be drawn before DRE or other prostate manipulations)	<ul style="list-style-type: none">Individuals aged 45-80No DRE in previous 4 daysNo previous prostate cancer diagnosisNo treatment of BPH, invasive urologic procedure with secondary PSA evaluation, or 5-ARI therapy in past 6 months
Specimen type	1.5 mL serum (critical frozen)	4 mL serum (refrigerated or frozen)
Testing location	In-house at ARUP, under standardized conditions in a CLIA- and CAP-certified lab	Sendout
Turnaround time	Results within 1-7 days (average 4-6 days)	3-6 days
FDA approval	YES	YES

For pricing information, please contact your ARUP Account Executive.

BPH, benign prostatic hyperplasia; DRE, digital rectal examination; PSA, prostate-specific antigen

For more information about prostate cancer screening, visit arupconsult.com/content/prostate-cancer.



*A nonprofit enterprise of the University of Utah
and its Department of Pathology*

aruplab.com/PHI-1

